Urothelial tumours of the upper urinary tract are rare, but their incidence increases in subjects suffering from phenacetin nephropathy, Balkan nephropathy and infected pyelic calculi. In order to act on the urothelium through the urinary way, a cancerigenic substance must (1) be eliminated with the urine; (2) be absorbed by the urothelium; (3) remain in the tissue for a certain length of time. Any situation leading to a prolongation of intra-tissue stasis favours the action of cancerigenic substances. The hypothesis is put forward that interstitial nephritis, by impeding the reabsorption from the pelvis by pyelo-lymphatic reflux and by making more difficult the lymphatic drainage of the pyelic and ureter walls, leads to a condition favouring carcinogenesis, especially if the subject is exposed to contact with even not very active carcinogens. It is possible to foresee that in future the incidence of upper urinary tract tumours should increase in chronic uraemic patients under dialytic treatment and in transplant patients.

Keywords:
Upper urinary tract tumours, Interstitial nephritis, Phenacetin nephropathy, Balkan nephropathy, Renal pelvis lithiasis
This content is only available via PDF.
© 1979 S. Karger AG, Basel
1979
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.